Whooping cough, i.e. pertussis, is a globally distributed acute respiratory disease 1 . Whooping π -π stacking interactions observed for the pyridine ring with nearby Tyr59 and for the and ionic interactions with Arg9 and Arg67. In MDS, pose 1 showed stability and retained its square deviation (RMSD) of 0.9 Å (Fig. S4A) , and the RMSD for the ligand orientations differ 2 2 7
on average by 2.3 Å when the coordinates of PtxS1 are superposed over the backbone atoms. In binding pocket with an average 22 Å RMSD for the ligand based on superposing the PtxS1
coordinates from the simulation (Fig. S4B ). In contrast to NSC228155, NSC29193 is rigid and almost exclusively resulted in two docked in the PtxS1, hydrogen bonding with main-chain nitrogen and oxygen atoms of Tyr10 (Fig. 5C ).
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Additionally, NSC29193 forms π -cation interactions with Arg9, π -π stacking with Tyr63 and 2 3 5
hydrogen bonding with the side-chain hydroxyl group of Ser52. NSC29193, pose 2, is bound near
the location where the adenine ring of NAD + would be bound in the pertussis toxin, stacking 2 3 7
against the aromatic ring of Trp26 and hydrogen bonding with the main-chain oxygen atom of 2 3 8
Thr24 (Fig. 5D ) as well as forming ionic interactions with Arg9 and Arg13. During MDS, by the average 12 Å RMSD of the ligand with respect to the superposed coordinates of the toxin 2 4 8 from the simulation (Fig. S4D ). Taken together, docking and MDS resulted in identification of find the optimal toxin dosage, we titrated the pertussis AB 5 holotoxin and detected the ADP- incubation with inhibitor (0.1, 1, 10 and 50 µM) + 2 h with holotoxin (10 ng/mL) or ii) 1, 2, 3, 4
and 5 h pre-incubation with 50 µM inhibitor + 2 h with holotoxin (10 ng/mL). However,
compound NSC228155 inhibited the Gαi-specific ADP-ribosylation activity of holotoxin in a 2 6 5 concentration-dependent manner (Fig. 6B ). Some inhibitory action was evidenced with 0.1 and 1 2 6 6 µM of NSC228155, but 5 µM of NSC228155 resulted in a near complete inhibition of mono-
ADP-ribosylation of Gαi. Based on pixel intensity analysis of the anti-MAR signal, the IC 50 of 2 6 8 NSC228155 inhibitory effect was 2.35 µM (Fig. 6C ).
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Having established NSC228155 as a potent inhibitor of pertussis toxin in living HEK293T ( Fig. 6D) . However, visual alterations, including partial cell detachment, was detected in
HEK293T cell monolayers upon titration of NSC228155 up to 50 µM in the 2.5 h Gαi ADP- We report the identification of the first small molecular weight compounds inhibiting the ADP- activity of pertussis toxin is important for the pathological effects of pertussis toxin. Seven-day- ART-activity fully survived a challenge, which caused 100% mortality with the parental strain of inducing leukocytosis in mice in doses that were 100-fold more than the median lethal dose of pertussis toxin might prove beneficial in the treatment of whooping cough.
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Compound library screening was made possible due to our ability to purify mg-levels of a between Cys41 and Cys201 12, 13 . Our truncation approach bypasses the need for disulfide bond 3 0 7 reduction 27 and extensive conformational movement of the C-terminus 12, 13 to activate PtxS1,
which inside the host cell has also been proposed to involve proteolysis 28 .
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We made an initial attempt to identify PtxS1 inhibitory compounds from molecules (n = 32,
see Table S2 ) known to inhibit the ART-activity of human diphtheria toxin-like ADP-
ribosyltransferases (ARTDs/PARPs). We envisioned that some of these compounds, which target
the ARTD/PARP NAD + -binding pockets, could provide a fast track to antibiotic development via
repurposing drug strategy, due to the current FDA-approvals in cancer therapy. However, none of
these compounds significantly inhibited the NAD + -consumption activity of rPtxS1 in the
presence of rGαi. Therefore, we decided to screen a diversity set compound library (n = 1,695) evidenced by the independent in vitro ADP-ribose conjugation assay (see Fig. 4A ), i.e. validating the primary screening hits in alternative and independent in vitro assays. In summary, NSC228155, but not NSC29193, was a potent inhibitor of pertussis holotoxin-mediated ADP-
ribosylation of Gαi in living HEK293T cells. We analyzed multiple different experimental set- approaches there appears to be no published information on NSC29193. Accordingly, the cell 3 4 3 permeability of NSC29193 is not known, but might be weak and thus explain our negative 3 4 4 inhibitory data. In sharp contrast, we detected a near complete inhibition of the Gαi ADP-
ribosylation with 5 µM NSC228155 (see Fig. 6 ). In part, this could relate to the fact that concentrations.
Resurgence of whooping cough has been witnessed even in highly vaccinated populations 1-3 , and
currently there are no specific therapeutics to treat whooping cough. Macrolide antibiotics, when toxin might prove beneficial in the treatment of whooping cough, especially in young children
who still lack the vaccine-induced protection against whooping cough. In this respect, several 3 6 9 drug modes of action could be envisioned, including to inhibit -i) secretion from the bacterium,
ii) host cell recognition, iii) endocytosis, iv) intracellular trafficking, and v) ADP-ribosylation in mouse and baboon models 33 . Our current study shows that small molecular weight compounds inhibiting the ADP-ribosyltransferase activity of pertussis toxin might also have therapeutic potential. Similar findings have been published on some other ADP-ribosylating bacterial toxins, pertussis toxin ADP-ribosyltransferase activity in whooping cough. Expression plasmids -i) rPtxS1-wt Synthetic DNA fragment (Eurofins Genomics) encoding for
amino acids D35-I221 of Bordetella pertussis strain Tohama I (UniProt_P04977) was cloned of PtxS1. ii) rPtxS1-Q127D/E129D pET15b-rPtxS1 plasmid was linearized with PCR using 5'- (GATAGCGATTATCTGGCACACCGGCGCATTCCG, mutagenic nucleotides underlined) and
prAPV-352 (GTAGGTGGCCAGCGCGCCGGCGAGGATACG). The PCR product was gel-
isolated, re-ligated and transformed to acquire the mutant plasmid. iii) rGαi-wt Synthetic DNA fragment (GenScript) encoding for E. coli codon-optimized full-length human Gαi (isoform 1,
UniProt_P63096-1) was cloned into pNIC-Bsa4 (Structural Genomics Consortium) using the (MHHHHHHSSGVDLGTENLYFQS-Gαi). iii) rGαi-Cys351Ala rGαi-encoding plasmid was 4 0 0 used as a template in PCR to amplify Cys351Ala-mutant-encoding mutant allele using allowing expression of an N-terminally HIS-tagged rGαi-Cys351Ala mutant similar to rGαi-wt.
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All expression plasmids were verified by sequencing. density at 600 nm reached 1 (typically 3-5 h), and temperature was reduced to 18°C. Bacteria were collected after 24 h by centrifugation and were either frozen to -80°C as pellets, in lysis 4 1 6 buffer or directly used for purification. Pefabloc protease inhibitor (Roche, 11585916001) was 4 1 7 added to 0.1 mM in the thawed biomass in lysis buffer [100 mM Hepes (pH 7.5), 500 mM NaCl, proteins were eluted with elution buffer [100mM Hepes (pH 7.5), 500 mM NaCl, 10% (w/v) fractions were pooled, concentrated using a 10 kDa cut-off concentrator (Thermo Scientific), analyzed by DSF using a CFX96 Real-Time PCR detection system (Bio-Rad). rGαi, rGαi-mutant
and rPtxS1 at a concentration of 0.2 mg/mL was used in 20 mM Hepes (pH 7.5), 500 mM NaCl, were determined by using the CFX96 Real-Time PCR detection system (Bio-Rad) software. (pH 7.5), 500 mM NaCl and 10% (w/v) glycerol. The membrane fraction was prepared 4 6 5 essentially as described in 37 . 80% confluent 10 cm cell culture plate of HEK293T cells was The cells were incubated at 4°C for 1 h in rotation to allow them to swell and partially lyse. The
partial lysates were drawn 20 times through 27-gauge needles and centrifuged with low speed 4 7 2
(600 × g, 4°C, 10 min) to pellet the nuclei and insoluble cell debris. The low-speed supernatant
was subjected to high-speed centrifugation (16100 × g, 4°C, 30 min) to pellet the membranes.
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The membranes were resolubilized into 50 μ L of 50 mM Hepes (pH 7.5), 200 mM NaCl, 1 mM 4 7 5
EDTA and 10 mM DTT, 0.3% (w/v) SDS and 2% Triton X-100 supplemented with protease and
phosphatase inhibitors, in concentration as described above. Protein concentration was measured
with Bradford assay. The ADP-ribosylation reactions were carried out at room temperature for 3
h with shaking at 300 rpm. Reactions were stopped by addition of Laemmli loading dye to 1 × 4 7 9
and heating for 10 minutes at 95°C. The samples were run on SDS-PAGE and transferred to ribose with a rabbit polyclonal anti-mono-ADP-ribose (1:1000) antibody (Hottiger-laboratory). Biotechnology) for 3 h at 4°C in rotation and washed thrice with TBST for ten minutes each time.
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All membranes were subsequently developed with WesternBright ECL (Advansta) and imaged Reactions were stopped by addition of Laemmli loading dye to 1 × and heating for 3 minutes at 5 0 2
90°C. The samples were run on SDS-PAGE and transferred to nitrocellulose membranes, were incubated with streptavidin conjugated to horse radish peroxidase (1:7000) (PerkinElmer, blocking buffer . Blots were incubated at room temperature for 2 h, followed (NSC288155 and NSC29193) was analyzed using 500 nM rPtxS1, 2 µM rGαi and 200 µM of TBST after which chemiluminescent substrate (Advansta, WesternBright Quantum) was added
and subsequent chemiluminescence was detected using Hidex Sense microplate reader (Hidex). In vitro NAD + consumption assay -i) basic reaction set-up Reactions were carried out in a U- with excitation and emission wavelengths set at 372 and 444 nm, respectively. Maximum signal
was defined as the NAD + buffer control and the minimum signal was the rPtxS1-catalyzed containing buffer. The assay was optimized to reach 60% NAD + consumption. The optimized 5 3 7
conditions for the assay are 125 nM rPtxS1, 500 nM NAD + and 1 µM rGαi. The reaction has substrate-independent NAD + consumption activity of rPtxS1, identical conditions were used same. Three plates were made on one day while second and third days had one plate each. Each background, screening window coefficient (Z') were calculated as described previously 22, 23 . iii) Compounds displaying inhibition more than 50% were considered as hits. Compound library for program repository (https://dtp.cancer.gov). After the screening, we re-ordered the primary hit were analyzed to identify pan-assay interference compounds or aggregators (zinc15.docking.org). maintaining a robust signal. Compounds were tested from a concentration range of (100-0.01
